共 50 条
Observations and findings during the development of a subnormothermic/normothermic long-term ex vivo liver perfusion machine
被引:3
|作者:
Schuler, Martin J.
[1
]
Becker, Dustin
[1
]
Mueller, Matteo
[2
]
Bautista Borrego, Lucia
[2
]
Mancina, Leandro
[2
]
Huwyler, Florian
[3
]
Binz, Jonas
[1
]
Hagedorn, Catherine
[2
]
Schaer, Beatrice
[4
]
Gygax, Erich
[5
]
Weisskopf, Miriam
[6
]
Sousa Da Silva, Richard Xavier
[2
]
Antunes Crisostomo, Joao Miguel
[1
]
Dutkowski, Philipp
[2
]
Rudolf von Rohr, Philipp
[7
]
Clavien, Pierre-Alain
[2
]
Tibbitt, Mark W.
[3
]
Eshmuminov, Dilmurodjon
[2
]
Hefti, Max
[1
]
机构:
[1] Univ Zurich, Wyss Zurich ETH Zurich, CH-8092 Zurich, Switzerland
[2] Univ Hosp Zurich, Dept Surg, Swiss Hepato Pancreato Biliary & Transplantat Ctr, Zurich, Switzerland
[3] Swiss Fed Inst Technol, Dept Mech & Proc Engn, Macromol Engn Lab, Zurich, Switzerland
[4] Securecell AG, Entwicklung Biomed Anwendungen, Urdorf, Switzerland
[5] Fumed AG, Forsch & Entwicklung, Muri, Switzerland
[6] Univ Zurich, Univ Zurich Hosp, Surg Res Ctr, Zurich, Switzerland
[7] Swiss Fed Inst Technol, Dept Mech & Proc Engn, Transport Proc & React Lab, Zurich, Switzerland
关键词:
clearance;
free hemoglobin;
hemolysis;
lactate;
liver perfusion;
long-term perfusion;
perfusion parameters;
subnormothermic;
normothermic perfusion;
CARDIOPULMONARY BYPASS;
BLOOD;
TRANSPLANTATION;
PRESERVATION;
METABOLISM;
PULSATILE;
MICROCIRCULATION;
HEMOGLOBIN;
DELIVERY;
ORGAN;
D O I:
10.1111/aor.14403
中图分类号:
R318 [生物医学工程];
学科分类号:
0831 ;
摘要:
Background Ex situliver machine perfusion at subnormothermic/normothermic temperature isincreasingly applied in the field of transplantation to store and evaluateorgans on the machine prior transplantation. Currently, various perfusionconcepts are in clinical and preclinical applications. Over the last 6 years ina multidisciplinary team, a novel blood based perfusion technology wasdeveloped to keep a liver alive and metabolically active outside of the bodyfor at least one week. Methods Within thismanuscript, we present and compare three scenarios (Group 1, 2 and 3) we werefacing during our research and development (R&D) process, mainly linked tothe measurement of free hemoglobin and lactate in the blood based perfusate. Apartfrom their proven value in liver viability assessment (ex situ), these twoparameters are also helpful in R&D of a long-term liver perfusion machine and moreover supportive in the biomedical engineering process. Results Group 1 ("good" liver on the perfusion machine) represents the best liver clearance capacity for lactate and free hemoglobin wehave observed. In contrast to Group 2 ("poor" liver on the perfusion machine), that has shown the worst clearance capacity for free hemoglobin. Astonishingly,also for Group 2, lactate is cleared till the first day of perfusion andafterwards, rising lactate values are detected due to the poor quality of theliver. These two perfusate parametersclearly highlight the impact of the organ quality/viability on the perfusion process. Whereas Group 3 is a perfusion utilizing a blood loop only (without a liver). Conclusion Knowing the feasible ranges (upper- and lower bound) and the courseover time of free hemoglobin and lactate is helpful to evaluate the quality ofthe organ perfusion itself and the maturity of the developed perfusion device. Freehemoglobin in the perfusate is linked to the rate of hemolysis that indicates how optimizing (gentle blood handling, minimizing hemolysis) the perfusion machine actually is. Generally, a reduced lactate clearancecapacity can be an indication for technical problems linked to the blood supplyof the liver and therefore helps to monitor the perfusion experiments.Moreover, the possibility is given to compare, evaluate and optimize developed liverperfusion systems based on the given ranges for these two parameters. Otherresearch groups can compare/quantify their perfusate (blood) parameters withthe ones in this manuscript. The presented data, findings and recommendations willfinally support other researchers in developing their own perfusion machine ormodifying commercially availableperfusion devices according to their needs.
引用
收藏
页码:317 / 329
页数:13
相关论文